logo-loader

Shield Therapeutics PLC: Hitting its clinical targets

Published: 01:44 30 Oct 2019 AEDT

Shield Therapeutics (LON:STX) has reported further data from its non-inferiority AEGIS H2H study of oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) versus intravenous ferric carboxymaltose (IV FCM), which is the standard second-line treatment for iron deficiency anaemia (IDA). The data from the multi-national Phase 3b randomised trial in inflammatory bowel disease (IBD) patients with IDA, supported the headline data reported in March, providing additional material to support commercialisation and reimbursement efforts in a global iron replacement market worth circa US$3bn.

The data, which were presented at the 27th United European Gastroenterology Week (UEG) by Dr Stefanie Howaldt, principal investigator of the AEGIS trial, included additional detail on the longer-term data out to 52 weeks and confirmed not only that the primary endpoints were met, but that Feraccru prevented the recurrence of IDA, providing a real oral alternative to IV iron. These outcomes provide strong support for the positioning of STX’s oral treatment for current and potential partners including in a broad preventative setting.

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC...

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

on 10/8/20